A group of 23 state attorneys general led by Florida told a federal court on Monday that the U.S. Centers for Disease Control and Prevention (CDC) lacks the legal authority to impose a nationwide transportation mask mandate to address COVID-19.
If you are not happy with the results below please do another search
50 search results for:
Drugmaker Gilead Sciences plans to announce on Tuesday that it will provide up to $5 million in grants to help a coalition of LGBTQ+ and human rights advocacy groups craft public health responses to monkeypox outbreaks, the company said.
Digital therapeutics are transitioning from curiosities to valuable additions to the pharmaceutical armamentarium, but they’re still not common in mainstream medicine.
Clinical-stage biopharma company Mersana Therapeutics unveiled a global collaboration with GlaxoSmithKline Monday that gives the industry behemoth the exclusive option to co-develop and commercialize Mersana’s antibody-drug conjugate (ADC) XMT-2056.
The company plans to deliver by next year the order for the IV treatment, which would be a vital option for patients unable to swallow the oral pill as monkeypox symptoms include rashes and blisters in the mouth.
The European Medicines Agency (EMA) has started a rolling review of a variant-adapted COVID-19 vaccine from Pfizer and BioNTech, it said on Tuesday.
Novavax Inc. on Monday halved its full-year revenue forecast as it does not expect further sales of its COVID-19 shot this year in the United States in the face of a global supply glut and soft demand, sending its shares down 33%.
Shares of Global Blood Therapeutics (GBT) continue to surge in premarket trading after Pfizer officially announced it was acquiring the hematology-focused company for $5.4 billion in order to bolster its presence in the multi-billion dollar rare disease market.
On Monday, Boston biopharma Karuna Therapeutics released results from the Phase III EMERGENT-2 trial showing that KarXT (xanomeline-trospium), its lead candidate, can strongly reduce symptom severity in schizophrenia patients.
The U.S. Senate passed the Inflation Reduction Act on Sunday, with Vice President Kamala Harris casting the tie-breaking vote to settle the verdict, which was split 50-50 along party lines. The bill, which is expected to have wide-ranging implications for the pharmaceutical industry, will still need to go to the House of Representatives, but with a Democratic majority, it is expected to pass before the end of the week.